Epigenetic regulation of epithelial to mesenchymal transition

Current Cancer Drug Targets

Volumn 13, Issue 9, 2013, Pages 973-985

  Huangyang, Peiwei ^a   Shang, Yongfeng ^a,b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

DNMT inhibitors; EMT; Epigenetic regulation; Epigenetic therapy; HDAC inhibitors; Metastasis; MiRNAs

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BUTYRIC ACID; DNA METHYLTRANSFERASE 3A; ENTINOSTAT; EPIGALLOCATECHIN GALLATE; FLUCYTOSINE DEOXYRIBOSIDE; GEFITINIB; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; MICRORNA 107; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; N PHTHALOYLTRYPTOPHAN; PANOBINOSTAT; POLYCOMB REPRESSIVE COMPLEX 2; PROTEIN P53; RETINOIC ACID; ROMIDEPSIN; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; UVOMORULIN; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

BREAST CANCER; CUTANEOUS T CELL LYMPHOMA; DEACETYLATION; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HISTONE ACETYLATION; HISTONE METHYLATION; HUMAN; LUNG METASTASIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; REVIEW;

DNA METHYLATION; EPIGENESIS, GENETIC; EPITHELIAL-MESENCHYMAL TRANSITION; HISTONES; HUMANS; MICRORNAS; SIGNAL TRANSDUCTION;

EID: 84890835024     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/15680096113136660103     Document Type: Review

References (173)

1. Kalluri, R.; Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 2009, 119(6), 1420-1428.
2. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2(6), 442-454.
3. Roussos, E. T.; Keckesova, Z. AACR special conference on epithelial-mesenchymal transition and cancer progression and treatment. Cancer Res. 2010, 70(19), 7360-7364.
4. Hay, E. D. Role of cell-matrix contacts in cell migration and epithelial-mesenchymal transformation. Cell Differ. Dev. 1990, 32(3), 367-375.
5. Strutz, F.; Zeisberg, M. Role of basic fibroblast growth factor-2 in epithelial-mesenchymal transformation. Kidney Int. 2002, 61(5), 1714-1728.
6. Gupta, G. P.; Massague, J. Cancer metastasis: building a framework. Cell 2006, 127(4), 679-695.
7. Valastyan, S.; Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011, 147(2), 275-292.
8. Thiery, J. P.; Acloque, H. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139(5), 871-890.
9. Rhim, A. D.; Mirek, E. T. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148(1-2), 349-361.
10. Lopez-Novoa, J. M.; Nieto, M. A. Inflammation and EMT: an alliance towards organ fibrosis and cancer progression. EMBO Mol. Med. 2009, 1(6-7), 303-314.
11. Polyak, K.; Weinberg, R. A. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9(4), 265-273.
12. Mani, S. A.; Guo, W. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133(4), 704-715.
13. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 2011, 144(5), 646-674.
14. Hajra, K. M.; Chen, D. Y. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002, 62(6), 1613-1618.
15. Nieto, M. A. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 2002, 3(3), 155-166.
16. Comijn, J.; Berx, G. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell 2001, 7(6), 1267-1278.
17. Eger, A.; Aigner, K. DeltaEF1 is a transcriptional repressor of Ecadherin and regulates epithelial plasticity in breast cancer cells. Oncogene 2005, 24(14), 2375-2385.
18. Peinado, H.; Olmeda, D. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat. Rev. Cancer 2007, 7(6), 415-428.
19. Yang, J.; Mani, S. A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117(7), 927-939.
20. Kang, Y.; Massague, J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004, 118(3), 277-279.
21. Onder, T. T.; Gupta, P. B. Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res. 2008, 68(10), 3645-3654.
22. Sleeman, J. P.; Thiery, J. P. SnapShot: The epithelial-mesenchymal transition. Cell 2011, 145(1), 162 e161.
23. Yook, J. I.; Li, X. Y. Wnt-dependent regulation of the E-cadherin repressor snail. J. Biol. Chem. 2005, 280(12), 11740-11748.
24. Xu, J.; Lamouille, S. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009, 19(2), 156-172.
25. Vincent, T.; Neve, E. P. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelialmesenchymal transition. Nat. Cell Biol. 2009, 11(8), 943-950.
26. Stemmer, V.; de Craene, B. Snail promotes Wnt target gene expression and interacts with beta-catenin. Oncogene 2008, 27(37), 5075-5080.
27. Waddington, C. H. The epigenotype. 1942. Int. J. Epidemiol. 2012, 41(1), 10-13.
28. Berger, S. L.; Kouzarides, T. An operational definition of epigenetics. Genes Dev. 2009, 23(7), 781-783.
29. Rodriguez-Paredes, M.; Esteller, M. Cancer epigenetics reaches mainstream oncology. Nat. Med. 2011, 17(3), 330-339.
30. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16(1), 6-21.
31. Lombaerts, M.; van Wezel, T. E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br. J. Cancer 2006, 94(5), 661-671.
32. Jones, P. A.; Baylin, S. B. The epigenomics of cancer. Cell 2007, 128(4), 683-692.
33. Pandiyan, K.; You, J. S. Functional DNA demethylation is accompanied by chromatin accessibility. Nucleic Acids Res. 2013, 41(7), 3973-3985.
34. Baylin, S. B.; Jones, P. A. A decade of exploring the cancer epigenome-biological and translational implications. Nat. Rev. Cancer 2011, 11(10), 726-734.
35. McGarvey, K.M.; Fahrner, J. A. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 2006, 66(7), 3541-3549.
36. Fuks, F.; Hurd, P. J. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 2003, 278(6), 4035-4040.
37. Lande-Diner, L.; Zhang, J. Role of DNA methylation in stable gene repression. J. Biol. Chem. 2007, 282(16), 12194-12200.
38. Lai, A. Y.; Wade, P. A. Cancer biology and NuRD: a multifaceted chromatin remodelling complex. Nat. Rev. Cancer 2011, 11(8), 588-596.
39. Li, Q.; Shi, L. Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14. Cancer Res. 2011, 71(21), 6899-6908.
40. Wang, Y.; Zhang, H. LSD1 is a subunit of the NuRD complex and targets the metastasis programs in breast cancer. Cell 2009, 138(4), 660-672.
41. Vrba, L.; Jensen, T. J. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS ONE 2010, 5(1), e8697.
42. Sinkkonen, L.; Hugenschmidt, T. MicroRNAs control de novo DNA methylation through regulation of transcriptional repressors in mouse embryonic stem cells. Nat. Struct. Mol. Biol. 2008, 15(3), 259-267.
43. Wu, S. C.; Zhang, Y. Active DNA demethylation: many roads lead to Rome. Nat. Rev. Mol. Cell Biol. 2010, 11(9), 607-620.
44. Goll, M. G.; Bestor, T. H. Eukaryotic cytosine methyltransferases. Annu. Rev. Biochem. 2005, 74, 481-514.
45. Wilson, A. S.; Power, B. E. DNA hypomethylation and human diseases. Biochim. Biophys. Acta 2007, 1775(1), 138-162.
46. McDonald, O. G.; Wu, H. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat. Struct. Mol. Biol. 2011, 18(8), 867-874.
47. Dumont, N.; Wilson, M. B. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc. Natl. Acad. Sci. USA 2008, 105(39), 14867-14872.
48. Hennessy, B. T.; Gonzalez-Angulo, A. M. Characterization of a naturally occurring breast cancer subset enriched in epithelial-tomesenchymal transition and stem cell characteristics. Cancer Res. 2009, 69(10), 4116-4124.
49. Yoshiura, K.; Kanai, Y. Silencing of the E-cadherin invasionsuppressor gene by CpG methylation in human carcinomas. Proc. Natl. Acad. Sci. U S A 1995, 92(16), 7416-7419.
50. Li, B.; Carey, M. The role of chromatin during transcription. Cell 2007, 128(4), 707-719.
51. Landt, S.G.; Marinov, G.K. ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia. Genome Res 2012, 22(9), 1813-1831.
52. Glozak, M. A.; Seto, E. Histone deacetylases and cancer. Oncogene 2007, 26(37), 5420-5432.
53. Kooistra, S. M.; Helin, K. Molecular mechanisms and potential functions of histone demethylases. Nat. Rev. Mol. Cell Biol. 2012, 13(5), 297-311.
54. Campos, E. I.; Reinberg, D. Histones: annotating chromatin. Annu. Rev. Genet. 2009, 43, 559-599.
55. Dawson, M. A.; Kouzarides, T. Cancer epigenetics: from mechanism to therapy. Cell 2012, 150(1), 12-27.
56. Chi, P.; Allis, C. D. Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 2010, 10(7), 457-469.
57. Liu, Y. N.; Lee, W. W. Regulatory mechanisms controlling human E-cadherin gene expression. Oncogene 2005, 24(56), 8277-8290.
58. Soutoglou, E.; Viollet, B. Transcription factor-dependent regulation of CBP and P/CAF histone acetyltransferase activity. EMBO J. 2001, 20(8), 1984-1992.
59. Abell, A. N.; Jordan, N. V. MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. Cell Stem Cell 2011, 8(5), 525-537.
60. Abell, A. N.; Granger, D. A. Trophoblast stem cell maintenance by fibroblast growth factor 4 requires MEKK4 activation of Jun Nterminal kinase. Mol. Cell. Biol. 2009, 29(10), 2748-2761.
61. Strahl, B. D.; Allis, C. D. The language of covalent histone modifications. Nature 2000, 403(6765), 41-45.
62. Cano, A.; Perez-Moreno, M. A. The transcription factor snail controls epithelial-mesenchymal transitions by repressing Ecadherin expression. Nat. Cell Biol. 2000, 2(2), 76-83.
63. Peinado, H.; Ballestar, E. Snail mediates E-cadherin repression by the recruitment of the Sin3A/histone deacetylase 1 (HDAC1)/ HDAC2 complex. Mol. Cell. Biol. 2004, 24(1), 306-319.
64. Kaimori, A.; Potter, J. J. Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-tomesenchymal transition in hepatocytes. Hepatology 2010, 52(3), 1033-1045.
65. Tripathi, M. K.; Misra, S. Regulation of BRCA2 gene expression by the SLUG repressor protein in human breast cells. J. Biol. Chem. 2005, 280(17), 17163-17171.
66. Shi, Y.; Sawada, J. Coordinated histone modifications mediated by a CtBP co-repressor complex. Nature 2003, 422(6933), 735-738.
67. Fu, J.; Qin, L. The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res. 2011, 21(2), 275-289.
68. Fujita, N.; Jaye, D. L. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003, 113(2), 207-219.
69. Wu, M. Z.; Tsai, Y. P. Interplay between HDAC3 and WDR5 is essential for hypoxia-induced epithelial-mesenchymal transition. Mol. Cell 2011, 43(5), 811-822.
70. Mani, S. A.; Barton, M. C. HDAC3 at the fulcrum of an epithelialmesenchymal balance. Mol. Cell 2011, 43(5), 697-698.
71. Dillon, S. C.; Zhang, X. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol. 2005, 6(8), 227.
72. Shi, B.; Liang, J. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol. Cell. Biol. 2007, 27(14), 5105-5119.
73. Herranz, N.; Pasini, D. Polycomb complex 2 is required for Ecadherin repression by the Snail1 transcription factor. Mol. Cell. Biol. 2008, 28(15), 4772-4781.
74. Pasini, D.; Bracken, A. P. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J. 2004, 23(20), 4061-4071.
75. Bernstein, B. E.; Mikkelsen, T. S. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125(2), 315-326.
76. Tsai, M. C.; Manor, O. Long noncoding RNA as modular scaffold of histone modification complexes. Science 2010, 329(5992), 689-693.
77. van der Vlag, J.; Otte, A. P. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat. Genet. 1999, 23(4), 474-478.
78. Furuno, K.; Masatsugu, T. Association of Polycomb group SUZ12 with WD-repeat protein MEP50 that binds to histone H2A selectively in vitro. Biochem. Biophys. Res. Commun. 2006, 345(3), 1051-1058.
79. Krause, C. D.; Yang, Z. H. Protein arginine methyltransferases: evolution and assessment of their pharmacological and therapeutic potential. Pharmacol. Ther. 2007, 113(1), 50-87.
80. Vire, E.; Brenner, C. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439(7078), 871-874.
81. Iliopoulos, D.; Lindahl-Allen, M. Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol. Cell 2010, 39(5), 761-772.
82. Leung, D. C.; Dong, K. B. Lysine methyltransferase G9a is required for de novo DNA methylation and the establishment, but not the maintenance, of proviral silencing. Proc. Natl. Acad. Sci. USA 2011, 108(14), 5718-5723.
83. Martin, C.; Zhang, Y. The diverse functions of histone lysine methylation. Nat. Rev. Mol. Cell Biol. 2005, 6(11), 838-849.
84. Dong, C.; Wu, Y. G9a interacts with Snail and is critical for Snailmediated E-cadherin repression in human breast cancer. J. Clin. Invest. 2012, 122(4), 1469-1486.
85. Dong, C.; Wu, Y. Interaction with Suv39H1 is critical for Snailmediated E-cadherin repression in breast cancer. Oncogene 2012, 32(11), 1351-1362.
86. Cedar, H.; Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 2009, 10(5), 295-304.
87. Fang, J.; Feng, Q. Purification and functional characterization of SET8, a nucleosomal histone H4-lysine 20-specific methyltransferase. Curr. Biol. 2002, 12(13), 1086-1099.
88. Yang, F.; Sun, L. SET8 promotes epithelial-mesenchymal transition and confers TWIST dual transcriptional activities. EMBO J. 2012, 31(1), 110-123.
89. Shi, Y.; Lan, F. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004, 119(7), 941-953.
90. Lan, F.; Nottke, A. C. Mechanisms involved in the regulation of histone lysine demethylases. Curr. Opin. Cell Biol. 2008, 20(3), 316-325.
91. Shi, Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat. Rev. Genet. 2007, 8(11), 829-833.
92. Wang, Y.; Shang, Y. Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Exp. Cell Res. 2013, 319(2), 160-169.
93. Shi, L.; Sun, L. Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis. Proc. Natl. Acad. Sci. USA 2011, 108(18), 7541-7546.
94. Guttilla, I. K.; Adams, B. D. ERalpha, microRNAs, and the epithelialmesenchymal transition in breast cancer. Trends Endocrinol. Metab. 2012, 23(2), 73-82.
95. Ramadoss, S.; Chen, X. Histone demethylase KDM6B promotes epithelial-mesenchymal transition. J. Biol. Chem. 2012, 287(53), 44508-44517.
96. Bartel, D. P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136(2), 215-233.
97. Ambros, V. The functions of animal microRNAs. Nature 2004, 431(7006), 350-355.
98. Spizzo, R.; Nicoloso, M. S. SnapShot: MicroRNAs in Cancer. Cell 2009, 137(3), 586-586 e581.
99. Ma, L.; Young, J. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell Biol. 2010, 12(3), 247-256.
100. Khew-Goodall, Y.; Goodall, G. J. Myc-modulated miR-9 makes more metastases. Nat. Cell Biol. 2010, 12(3), 209-211.
101. Hurteau, G. J.; Carlson, J. A. Overexpression of the microRNA hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin. Cancer Res. 2007, 67(17), 7972-7976.
102. Gregory, P. A.; Bert, A. G. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10(5), 593-601.
103. Korpal, M.; Lee, E. S. The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283(22), 14910-14914.
104. Gibbons, D. L.; Lin, W. Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev. 2009, 23(18), 2140-2151.
105. Cano, A.; Nieto, M. A. Non-coding RNAs take centre stage in epithelial-to-mesenchymal transition. Trends Cell Biol. 2008, 18(8), 357-359.
106. Dykxhoorn, D. M.; Wu, Y. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS ONE 2009, 4(9), e7181.
107. Korpal, M.; Ell, B. J. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 2011, 17(9), 1101-1108.
108. Burk, U.; Schubert, J. A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 2008, 9(6), 582-589.
109. Brabletz, S.; Brabletz, T. The ZEB/miR-200 feedback loop--a motor of cellular plasticity in development and cancer? EMBO Rep. 2010, 11(9), 670-677.
110. Liu, Y. N.; Yin, J. J. MiR-1 and miR-200 inhibit EMT via Slugdependent and tumorigenesis via Slug-independent mechanisms. Oncogene 2012, 32(3), 296-306.
111. Xiang, X.; Zhuang, X. miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT. Oncogene 2011, 30(31), 3440-3453.
112. Zhao, X.; Dou, W. MicroRNA-7 functions as an anti-metastatic microRNA in gastric cancer by targeting insulin-like growth factor-1 receptor. Oncogene 2012, 32(11), 1363-1372.
113. Cha, Y. H.; Kim, N. H. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle 2012, 11(7), 1273-1281.
114. Du, R.; Sun, W. Hypoxia-induced down-regulation of microRNA-34a promotes EMT by targeting the Notch signaling pathway in tubular epithelial cells. PLoS ONE 2012, 7(2), e30771.
115. Kong, W.; Yang, H. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol. Cell. Biol. 2008, 28(22), 6773-6784.
116. Childs, G.; Segall, J. E. Twists and turns of invasion. Nat. Cell Biol. 2012, 14(4), 337-339.
117. Li, X.; Zhang, Y. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol. Cancer Res. 2011, 9(7), 824-833.
118. Ma, L.; Teruya-Feldstein, J. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007, 449(7163), 682-688.
119. Meng, F.; Glaser, S. S. Functional analysis of microRNAs in human hepatocellular cancer stem cells. J. Cell. Mol. Med. 2012, 16(1), 160-173.
120. Yin, G.; Chen, R. TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010, 29(24), 3545-3553.
121. Chang, C. J.; Chao, C. H. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 2011, 13(3), 317-323.
122. Martello, G.; Rosato, A. A MicroRNA targeting dicer for metastasis control. Cell 2010, 141(7), 1195-1207.
123. Davalos, V.; Moutinho, C. Dynamic epigenetic regulation of the microRNA-200 family mediates epithelial and mesenchymal transitions in human tumorigenesis. Oncogene 2012, 31(16), 2062-2074.
124. Egger, G.; Liang, G. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004, 429(6990), 457-463.
125. Jones, P. A.; Taylor, S. M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980, 20(1), 85-93.
126. Kristensen, L. S.; Nielsen, H. M. Epigenetics and cancer treatment. Eur. J. Pharmacol. 2009, 625(1-3), 131-142.
127. Brock, M. V.; Gou, M. Prognostic importance of promoter hypermethylation of multiple genes in esophageal adenocarcinoma. Clin. Cancer Res. 2003, 9(8), 2912-2919.
128. Corn, P. G.; Smith, B. D. E-cadherin expression is silenced by 5' CpG island methylation in acute leukemia. Clin. Cancer Res. 2000, 6(11), 4243-4248.
129. Chen, Q.; Lipkina, G. Promoter methylation regulates cadherin switching in squamous cell carcinoma. Biochem. Biophys. Res. Commun. 2004, 315(4), 850-856.
130. Ribeiro-Filho, L. A.; Franks, J. CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer. Mol. Carcinog. 2002, 34(4), 187-198.
131. Nam, J. S.; Ino, Y. 5-aza-2'-deoxycytidine restores the E-cadherin system in E-cadherin-silenced cancer cells and reduces cancer metastasis. Clin. Exp. Metastasis 2004, 21(1), 49-56.
132. Yoo, C. B.; Jones, P. A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 2006, 5(1), 37-50.
133. Rao, S. P.; Rechsteiner, M. P. Zebularine reactivates silenced Ecadherin but unlike 5-Azacytidine does not induce switching from latent to lytic Epstein-Barr virus infection in Burkitt's lymphoma Akata cells. Mol. Cancer 2007, 6, 3.
134. Savickiene, J.; Treigyte, G. Antileukemic activity of combined epigenetic agents, DNMT inhibitors zebularine and RG108 with HDAC inhibitors, against promyelocytic leukemia HL-60 cells. Cell. Mol. Biol. Lett. 2012, 17(4), 501-525.
135. Ateeq, B.; Unterberger, A. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia 2008, 10(3), 266-278.
136. Guo, Y.; Pakneshan, P. Regulation of DNA methylation in human breast cancer. Effect on the urokinase-type plasminogen activator gene production and tumor invasion. J. Biol. Chem. 2002, 277(44), 41571-41579.
137. Wu, Y.; Lin, Y. Inhibition of invasion and up-regulation of Ecadherin expression in human malignant melanoma cell line A375 by (-)-epigallocatechin-3-gallate. J. Huazhong Univ. Sci. Technolog. Med. Sci. 2008, 28(3), 356-359.
138. Savickiene, J.; Treigyte, G. DNA methyltransferase inhibitor RG108 and histone deacetylase inhibitors cooperate to enhance NB4 cell differentiation and E-cadherin re-expression by chromatin remodelling. Cell Biol. Int. 2012, 36(11), 1067-1078.
139. Mai, A.; Altucci, L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int. J. Biochem. Cell Biol. 2009, 41(1), 199-213.
140. Finnin, M. S.; Donigian, J. R. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401(6749), 188-193.
141. von Burstin, J.; Eser, S. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/ HDAC2 repressor complex. Gastroenterology 2009, 137(1), 361-371, 371 e361-365.
142. Mai, A.; Massa, S. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med. Res. Rev. 2005, 25(3), 261-309.
143. Nebbioso, A.; Clarke, N. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat. Med. 2005, 11(1), 77-84.
144. Qian, D. Z.; Kato, Y. Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin. Cancer Res. 2006, 12(2), 634-642.
145. Kondo, K.; Kohno, N. Decreased MUC1 expression induces Ecadherin-mediated cell adhesion of breast cancer cell lines. Cancer Res. 1998, 58(9), 2014-2019.
146. Barshishat, M.; Polak-Charcon, S. Butyrate regulates E-cadherin transcription, isoform expression and intracellular position in colon cancer cells. Br. J. Cancer 2000, 82(1), 195-203.
147. Masuda, T.; Saito, H. Up-regulation of E-cadherin and I-catenin in human hepatocellular carcinoma cell lines by sodium butyrate and interferon-alpha. In Vitro Cell. Dev. Biol. Anim. 2000, 36(6), 387-394.
148. Takai, N.; Desmond, J. C. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin. Cancer Res. 2004, 10(3), 1141-1149.
149. Gottlicher, M.; Minucci, S. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001, 20(24), 6969-6978.
150. Law, M. E.; Corsino, P.E. Glucocorticoids and histone deacetylase inhibitors cooperate to block the invasiveness of basal-like breast cancer cells through novel mechanisms. Oncogene 2013, 32(10), 1316-1329.
151. Bruzzese, F.; Leone, A. HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. J. Cell. Physiol. 2011, 226(9), 2378-2390.
152. Ou, J. N.; Torrisani, J. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem. Pharmacol. 2007, 73(9), 1297-1307.
153. Heemskerk, B.; Kvistborg, P. The cancer antigenome. EMBO J. 2013, 32(2), 194-203.
154. Coral, S.; Covre, A. Epigenetic remodelling of gene expression profiles of neoplastic and normal tissues: immunotherapeutic implications. Br. J. Cancer 2012, 107(7), 1116-1124.
155. Coral, S.; Sigalotti, L. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J. Cell. Physiol. 2006, 207(1), 58-66.
156. Fonsatti, E.; Nicolay, H. J. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin. Cancer Res. 2007, 13(11), 3333-3338.
157. De Schutter, H.; Nuyts, S. Radiosensitizing potential of epigenetic anticancer drugs. Anticancer Agents Med. Chem. 2009, 9(1), 99-108.
158. Weiler, J.; Hunziker, J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther. 2006, 13(6), 496-502.
159. Ebert, M. S.; Neilson, J. R. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat. Methods 2007, 4(9), 721-726.
160. Garzon, R.; Marcucci, G. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat. Rev. Drug Discov. 2010, 9(10), 775-789.
161. Krutzfeldt, J.; Rajewsky, N. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438(7068), 685-689.
162. Elmen, J.; Lindow, M. LNA-mediated microRNA silencing in nonhuman primates. Nature 2008, 452(7189), 896-899.
163. Ma, L.; Reinhardt, F. Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model. Nat. Biotechnol. 2010, 28(4), 341-347.
164. Lu, Y.; Xiao, J. A single anti-microRNA antisense oligodeoxyribonucleotide (AMO) targeting multiple microRNAs offers an improved approach for microRNA interference. Nucleic Acids Res. 2009, 37(3), e24.
165. Cohen, S. M. Use of microRNA sponges to explore tissue-specific microRNA functions in vivo. Nat. Methods 2009, 6(12), 873-874.
166. Xia, H.; Hui, K. M. MicroRNAs involved in regulating epithelialmesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 2012, 19(11), 723-730.
167. Akinc, A.; Zumbuehl, A. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 2008, 26(5), 561-569.
168. Thomas, M.; Lange-Grunweller, K. The proto-oncogene Pim-1 is a target of miR-33a. Oncogene 2012, 31(7), 918-928.
169. Kota, J.; Chivukula, R. R. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 2009, 137(6), 1005-1017.
170. Tsai, J. H.; Donaher, J. L. Spatiotemporal regulation of epithelialmesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012, 22(6), 725-736.
171. Ocana, O. H.; Corcoles, R. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1. Cancer Cell 2012, 22(6), 709-724.
172. Budhu, A.; Ji, J. The clinical potential of microRNAs. J. Hematol. Oncol. 2010, 337.
173. Hou, Z.; Peng, H. The LIM protein AJUBA recruits protein arginine methyltransferase 5 to mediate SNAIL-dependent transcriptional repression. Mol. Cell. Biol. 2008, 28(10), 3198-3207.